List of Excipients in Branded Drug METHYLDOPA AND HYDROCHLOROTHIAZIDE

Generic Drugs Containing METHYLDOPA AND HYDROCHLOROTHIAZIDE

Company	Ingredient	NDC	Excipient
Mylan Pharmaceuticals Inc	methyldopa and hydrochlorothiazide	0378-0507	CELLULOSE, MICROCRYSTALLINE
Mylan Pharmaceuticals Inc	methyldopa and hydrochlorothiazide	0378-0507	CROSCARMELLOSE SODIUM
Mylan Pharmaceuticals Inc	methyldopa and hydrochlorothiazide	0378-0507	D&C YELLOW NO. 10
Mylan Pharmaceuticals Inc	methyldopa and hydrochlorothiazide	0378-0507	FD&C BLUE NO. 1
Mylan Pharmaceuticals Inc	methyldopa and hydrochlorothiazide	0378-0507	FD&C YELLOW NO. 6
Mylan Pharmaceuticals Inc	methyldopa and hydrochlorothiazide	0378-0507	HYPROMELLOSE

What are the Most Frequently-Used Excipients in METHYLDOPA AND HYDROCHLOROTHIAZIDE?

# Of NDCs	Excipient
1	CELLULOSE, MICROCRYSTALLINE
1	CROSCARMELLOSE SODIUM
1	D&C YELLOW NO. 10
1	FD&C BLUE NO. 1
1	FD&C YELLOW NO. 6
1	HYPROMELLOSE

Last updated: September 16, 2026

Executive summary: Methyldopa/hydrochlorothiazide is an old, immediate-release fixed-dose combination with no meaningful remaining patent barrier. Its commercial value is limited by generic price competition, declining use of methyldopa outside pregnancy-related hypertension, and the lack of a clear clinical advantage over newer antihypertensive combinations. The strongest opportunity is a low-cost, supply-reliable generic or reformulated product aimed at institutional and pregnancy-related hypertension markets. Excipients should prioritize chemical stability, dissolution consistency, low moisture exposure, and broad global regulatory acceptability rather than differentiated drug delivery.

Methyldopa and Hydrochlorothiazide Excipient Strategy and Commercial Opportunities

What is the commercial position of methyldopa and hydrochlorothiazide?

Methyldopa/hydrochlorothiazide combines a centrally acting antihypertensive with a thiazide diuretic. Historical products included Aldoril, marketed in strengths such as methyldopa 250 mg/hydrochlorothiazide 15 mg, methyldopa 250 mg/hydrochlorothiazide 25 mg, and methyldopa 500 mg/hydrochlorothiazide 30 mg.[1]

The product is commercially mature. Its principal opportunity is generic supply, not premium innovation.

Commercial factor	Assessment
Drug class	Antihypertensive fixed-dose combination
Dosage form	Immediate-release oral tablet
Patent barrier	Historical patents expired or commercially irrelevant
Regulatory exclusivity	No meaningful current new-drug exclusivity expected
Biosimilar exposure	None; both active ingredients are synthetic small molecules
Primary commercial route	ANDA or jurisdiction-specific generic application
Differentiation potential	Manufacturing reliability, packaging, tablet performance, and supply continuity
Main demand segments	Institutional procurement, low-cost chronic therapy, selected pregnancy-related hypertension use
Pricing power	Low
Clinical growth potential	Limited

Methyldopa remains recognized for hypertension during pregnancy, although other agents are commonly preferred depending on jurisdiction and clinical circumstances. Hydrochlorothiazide is widely available as a single agent and in combinations with newer antihypertensives. This makes the fixed combination less attractive for routine first-line treatment.

When does methyldopa and hydrochlorothiazide lose exclusivity?

Methyldopa/hydrochlorothiazide has no meaningful remaining market exclusivity based on the age of the combination and the long commercial history of both active ingredients. Methyldopa was introduced in the 1960s, while hydrochlorothiazide has been marketed since the 1950s.[2,3]

Patent and exclusivity timeline

Milestone	Approximate status
Methyldopa introduced	1960s
Hydrochlorothiazide introduced	1950s
Historical fixed-dose products	Mid-20th century onward
Core composition patents	Expired
Original-product regulatory exclusivity	Expired
Current generic market	Mature
Current patent cliff	No discrete near-term cliff

Any residual patent issue would most likely involve a later formulation, manufacturing process, or jurisdiction-specific product rather than the basic combination itself. A sponsor should not assume that a historic brand name indicates active patent protection.

What is the FDA regulatory status of methyldopa and hydrochlorothiazide?

Methyldopa and hydrochlorothiazide are established FDA-approved active ingredients. The regulatory route for a new U.S. product depends on whether the proposed product can be shown to be therapeutically equivalent to an eligible reference listed drug.

An ANDA is the most efficient route when the applicant can match the reference product in active ingredients, strength, dosage form, route of administration, and relevant performance attributes. If no suitable reference listed drug is available, or if the sponsor proposes a meaningful formulation or labeling difference, a 505(b)(2) application may be more appropriate under the facts of the product.

FDA development issues

The sponsor would need to address:

• Comparative dissolution across relevant pH conditions.
• Assay and content uniformity for both active ingredients.
• Stability of methyldopa under heat and humidity.
• Bioequivalence requirements for the selected strength or strengths.
• Impurity control, including degradation products.
• Manufacturing controls for a low-dose thiazide component.
• Labeling consistency with the applicable reference product.
• Drug interaction and concomitant-use information.

Because hydrochlorothiazide is present at a lower dose than methyldopa in several historical strengths, blend uniformity is a critical process-control issue.

What excipients are appropriate for methyldopa/hydrochlorothiazide tablets?

The preferred platform is a conventional immediate-release compressed tablet using well-established, compendial excipients. The formulation should avoid unnecessary complexity.

Recommended excipient architecture

Formulation function	Suitable excipient classes	Strategic rationale
Diluent	Microcrystalline cellulose, lactose, dibasic calcium phosphate, or a justified combination	Controls tablet size and improves content uniformity
Binder	Povidone or pregelatinized starch	Supports granule strength and robustness
Disintegrant	Crospovidone, croscarmellose sodium, or sodium starch glycolate	Supports rapid and reproducible tablet breakup
Lubricant	Magnesium stearate or sodium stearyl fumarate	Enables compression and ejection
Glidant	Colloidal silicon dioxide	Improves powder flow
Film coat	Hypromellose-based coating system	Supports identification, handling, and moisture control
Colorant	Approved iron oxides or other jurisdictionally accepted colorants	Strength differentiation and product identification

The final selection depends on the physical properties of the drug substances, manufacturing process, and target markets. Excipients should be selected from established regulatory databases and supported by supplier qualification and compendial testing.

What excipient risks are specific to methyldopa?

Methyldopa can present stability and process challenges. The formulation strategy should address:

1. Moisture exposure during granulation and storage.
2. Oxidative degradation and discoloration.
3. Sensitivity to process heat where applicable.
4. Blend segregation caused by differences in particle size and density.
5. Low-dose hydrochlorothiazide distribution within the final blend.
6. Dissolution variability after compression or coating.

A direct-compression process may reduce water and heat exposure, but it requires tightly controlled particle-size distribution and powder flow. Wet granulation can improve content uniformity and compressibility but introduces moisture and drying variables. Roller compaction is a potential intermediate option when the powder blend lacks sufficient flow or compactibility.

Should the product use a bilayer tablet?

A bilayer tablet is generally unnecessary for a standard methyldopa/hydrochlorothiazide product. It could separate incompatible ingredients or improve dose uniformity, but it raises tooling, validation, and scale-up costs. For a low-price generic, a single-layer tablet is usually the stronger commercial choice unless compatibility data justify separation.

What formulations are protected or commercially differentiated?

The core immediate-release tablet is unlikely to support meaningful exclusivity. Commercial differentiation would need to come from execution rather than broad composition claims.

Potential formulation concepts include:

• A moisture-protective film-coated tablet.
• A low-dust, high-uniformity tablet for institutional manufacturing.
• A scored tablet supporting dose adjustment.
• A lactose-free or low-lactose formulation.
• A product using a globally accepted excipient set.
• A packaging system with stronger humidity protection.
• A pediatric or liquid formulation, subject to stability and palatability requirements.
• A fixed-dose tablet optimized for a specific national treatment guideline.

Modified-release, orally disintegrating, chewable, and multiparticulate versions could create formulation differentiation, but they would also increase regulatory and clinical-development costs. The market is unlikely to support those investments without a defined procurement or clinical requirement.

What patent litigation and Paragraph IV risks affect the product?

No major current Paragraph IV controversy is expected for the basic methyldopa/hydrochlorothiazide combination. The relevant patents for the original combination and active ingredients are historically old.

Likely patent position

IP category	Risk assessment
Basic combination composition	Very low
Methyldopa composition claims	Expired
Hydrochlorothiazide composition claims	Expired
Immediate-release tablet claims	Low
Manufacturing-process claims	Potentially relevant only if a current supplier relies on them
Novel excipient system	Could create limited later-filed claims
Method-of-use claims	Limited practical blocking value for an old broad indication
Salt, polymorph, or prodrug claims	Unlikely to create a meaningful barrier for the established actives

A sponsor should still conduct a current patent search before launch because national rights, formulation patents, and supplier-owned process patents can differ. The strategic conclusion remains that patent clearance is unlikely to be the principal launch constraint.

What method-of-use patents protect methyldopa and hydrochlorothiazide?

Broad hypertension method-of-use protection is not expected to remain commercially significant. Methyldopa has long-standing clinical use in hypertension, including pregnancy-associated hypertension. Hydrochlorothiazide has broad use in hypertension and edema.

Potential method-of-use claim areas include:

• Treatment of hypertension in defined patient populations.
• Use at specific dose intervals.
• Combination treatment with other antihypertensive agents.
• Use in patients with renal or cardiovascular conditions.
• Pregnancy-related hypertension.

These areas are unlikely to create strong blocking rights for a conventional generic tablet. Method-of-use risk becomes more relevant only if the proposed labeling actively seeks a new indication or the product relies on a later, narrower patent claim.

How strong is the patent estate for methyldopa and hydrochlorothiazide?

The patent estate is weak for the established combination and does not support a premium branded strategy.

Patent-strength assessment

Criterion	Rating	Reason
Composition-of-matter protection	1/5	Historical protection expired
Fixed-dose combination protection	1/5	Old combination technology
Formulation protection	1-2/5	Conventional tablet platform
Method-of-use protection	1-2/5	Broad indications are longstanding
Manufacturing protection	2/5	Process claims may exist but are usually avoidable
Freedom-to-operate value	4/5	Low blocking risk for conventional development
Life-cycle management value	1-2/5	Limited clinical and commercial incentive

The strongest defensible intellectual property would likely involve a narrowly defined manufacturing process, impurity-control method, or differentiated dosage form. Such claims may protect a process but are unlikely to create a large market moat.

What generic launch scenarios exist?

Three launch scenarios are commercially realistic.

Scenario 1: Standard low-cost generic

The sponsor launches a conventional immediate-release tablet in one or more historical strengths. This is the lowest-risk path and the most likely to face price competition.

The main success factors are:

• Reliable API sourcing.
• Low-cost manufacturing.
• Strong content-uniformity controls.
• Sufficient stability data.
• Multi-market packaging.
• Consistent supply to wholesalers and institutional buyers.

Scenario 2: Institutional and public-procurement product

The sponsor targets hospitals, government tenders, humanitarian procurement, and markets where methyldopa remains regularly prescribed. This approach can produce volume but usually requires aggressive pricing, documentation, and supply guarantees.

Scenario 3: Differentiated pregnancy-hypertension product

A sponsor could position the product for pregnancy-related hypertension where methyldopa remains clinically recognized. The commercial opportunity is constrained because hydrochlorothiazide is not universally preferred for initiating hypertension treatment during pregnancy, and local guidelines vary.

A pregnancy-focused product would need:

• Clear labeling aligned with current clinical guidance.
• High supply reliability.
• Strong quality documentation.
• Packaging that supports adherence.
• Careful pharmacovigilance.

A marketing strategy that overstates pregnancy-specific advantages would create regulatory and compliance risk.

Which companies are challenging or competing with methyldopa and hydrochlorothiazide?

The main competitive threat does not come from a single branded challenger. It comes from therapeutic substitution and generic alternatives.

Direct competition

• Generic methyldopa tablets.
• Generic hydrochlorothiazide tablets.
• Other methyldopa-containing products.
• Historical or regionally marketed fixed-dose combinations.

Therapeutic competition

• Labetalol.
• Nifedipine and other calcium-channel blockers.
• Amlodipine.
• ACE inhibitor and hydrochlorothiazide combinations outside pregnancy.
• Angiotensin receptor blocker and hydrochlorothiazide combinations.
• Chlorthalidone and other thiazide-like diuretics.

The relevant manufacturers vary by market and procurement channel. In the United States, competition is primarily among generic manufacturers and distributors rather than large branded companies.

What manufacturing and IP barriers affect the product?

The principal barriers are operational rather than patent-based.

Manufacturing barriers

1. Achieving uniform distribution of low-dose hydrochlorothiazide.
2. Preventing methyldopa degradation during processing and storage.
3. Controlling tablet hardness without slowing dissolution.
4. Maintaining stability across hot and humid climates.
5. Qualifying suppliers for both active ingredients.
6. Managing multiple strengths without cross-contamination.
7. Establishing a robust cleaning-validation program.
8. Supporting international packaging and serialization requirements.

An integrated quality-by-design program should identify critical material attributes such as API particle size, bulk density, moisture content, and flow. Critical process parameters would likely include blending time, granulation endpoint, compression force, tablet weight, coating conditions, and packaging-line controls.

Packaging strategy

Aluminum-aluminum blister packaging provides stronger moisture protection than many lower-cost blister formats. High-density polyethylene bottles with desiccant can be suitable when supported by stability data. The best choice depends on target climate zones, distribution duration, and tender specifications.

For a low-margin product, packaging should be optimized for total cost of ownership rather than unit packaging cost alone. Product loss from humidity-related degradation can exceed the incremental cost of a better barrier package.

What licensing deals could support commercial entry?

Licensing opportunities are more likely to involve manufacturing, distribution, or regulatory infrastructure than drug substance rights.

Potential deal structures include:

• Contract manufacturing with an established generic producer.
• Regional commercialization rights.
• Technology transfer for a validated tablet process.
• API supply agreements with dual-source provisions.
• Co-development for a pediatric or liquid formulation.
• Public-sector supply agreements.
• Portfolio licensing that bundles methyldopa/hydrochlorothiazide with other antihypertensives.

A licensing arrangement has the strongest rationale where the partner already has:

• An approved manufacturing site.
• A recognized regulatory filing.
• Existing hospital or government accounts.
• Local pharmacovigilance capability.
• Reliable access to methyldopa API.

There is limited rationale for paying an upfront premium for historical brand rights unless the brand retains meaningful tender access or physician recognition in a specific market.

How does methyldopa/hydrochlorothiazide compare with newer antihypertensive combinations?

Attribute	Methyldopa/hydrochlorothiazide	Modern ARB/HCTZ or ACE inhibitor/HCTZ product
Patent position	Expired	Often expired or late-life
Routine first-line use	Limited	Broader in nonpregnant adults
Pregnancy use	Methyldopa has established use; combination requires guideline review	ACE inhibitors and ARBs are generally unsuitable during pregnancy
Dosing convenience	Fixed combination	Fixed combination
Adverse-effect burden	Methyldopa-related sedation, fatigue, liver and hematologic concerns; HCTZ metabolic effects	Class-specific renal, electrolyte, cough, angioedema, or metabolic effects
Commercial demand	Niche and declining	Larger and more stable
Differentiation	Mostly supply and quality	Often broader clinical positioning
Pricing	Low	Low to moderate depending on market

The combination may retain a role where methyldopa is specifically selected and a diuretic is clinically appropriate. It is poorly positioned as a broad growth product.

What revenue exposure and market opportunity exist?

Publicly reliable product-level revenue data are limited because the combination is generic, fragmented, and often sold through multiple regional labels. The market should be modeled through prescription volume, tender awards, and net price rather than historical branded sales.

Commercial opportunity by segment

Segment	Opportunity	Commercial logic
U.S. retail generic	Low	Limited demand and intense generic competition
U.S. institutional supply	Low to moderate	Value depends on supply continuity and contract access
Pregnancy-related hypertension markets	Moderate in selected countries	Methyldopa remains clinically recognized
Emerging markets	Moderate	Established use and lower-cost treatment needs
Premium branded product	Low	Weak exclusivity and limited differentiation
New delivery system	Low unless clinically justified	Development cost likely exceeds addressable demand
Public tenders	Moderate but margin constrained	Volume can offset low unit price

The best commercial case is a focused, multi-country generic platform with low manufacturing cost and dependable supply. A single-country retail launch is less attractive unless competition is unusually limited.

What is the geographic coverage of the opportunity?

Methyldopa use is strongest in jurisdictions where it remains embedded in pregnancy-hypertension guidelines or where low-cost legacy antihypertensives remain common. Regulatory requirements differ materially.

Geographic considerations

• United States: ANDA feasibility depends on reference-product and product-specific regulatory status.
• European Union: Generic or hybrid application requirements depend on the selected reference and national or centralized strategy.
• Emerging markets: Local registration, bioequivalence expectations, and tender access may determine value more than patent rights.
• Low- and middle-income markets: Heat and humidity stability, packaging, and supply reliability are critical.
• Countries with strong pregnancy-care programs: Methyldopa demand may be more durable, but combination use must be consistent with local treatment guidance.

A global excipient platform should avoid unnecessary excipients that create region-specific acceptability, labeling, or supply problems.

Key Takeaways

• Methyldopa/hydrochlorothiazide is a mature generic combination with no meaningful core patent barrier.
• The commercial opportunity is based on cost, quality, supply reliability, and geographic execution.
• A conventional immediate-release tablet is the most rational formulation.
• Excipients should support blend uniformity, rapid dissolution, moisture control, and methyldopa stability.
• Hydrochlorothiazide’s low dose makes content uniformity and segregation control central development risks.
• A single-layer film-coated tablet is generally preferable to a bilayer or modified-release product.
• Pregnancy-related hypertension is the most defensible niche, but combination use requires alignment with local clinical guidance.
• Biosimilar risk is irrelevant because both active ingredients are small molecules.
• The principal barriers are manufacturing, regulatory documentation, procurement access, and therapeutic substitution.
• Premium pricing and substantial life-cycle management are unlikely to be justified.

FAQs

Is methyldopa/hydrochlorothiazide still commercially viable?

Yes, but mainly as a low-cost generic or institutional product. Its viability depends on reliable demand in selected markets rather than broad growth.

Which excipient is most important for hydrochlorothiazide content uniformity?

No single excipient determines uniformity. Particle-size control, ordered blending, suitable dilution, and segregation-resistant processing are more important than the choice of one specific filler.

Can a company obtain new patents on a methyldopa/hydrochlorothiazide tablet?

Potentially, but claims would likely need to cover a novel formulation, manufacturing process, impurity-control method, or delivery system. Broad claims to the established combination are unlikely to be strong.

Is a liquid methyldopa/hydrochlorothiazide formulation commercially attractive?

Usually not without a defined pediatric, geriatric, or administration-related need. The product would face stability, taste, preservative, packaging, and dosing-accuracy challenges.

Does methyldopa/hydrochlorothiazide have biosimilar competition?

No. Biosimilar regulation applies to biological products. Methyldopa and hydrochlorothiazide are synthetic small-molecule drugs and compete through generic drug pathways.

References

1. Merck Sharp & Dohme. (1978). Aldoril product information.
2. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs.
3. U.S. National Library of Medicine. (2024). DailyMed: Methyldopa and hydrochlorothiazide product labeling.
4. U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations.
5. United States Pharmacopeia. (2024). United States Pharmacopeia and National Formulary.
6. American College of Obstetricians and Gynecologists. (2019). Clinical guidance for the management of hypertension in pregnancy. Obstetrics & Gynecology, 133(1), e26-e50.